Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy

The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.

Study Overview

• Status: Completed
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: Fulvestrant; Drug: Sapanisertib

Detailed Description

The drug being tested in this study is called sapanisertib. Sapanisertib is being tested to treat postmenopausal women with advanced or metastatic estrogen receptor (ER) positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer that has progressed during or after aromatase inhibitor (AI) therapy. This study will evaluate the efficacy and safety of combination of fulvestrant + daily sapanisertib and fulvestrant + weekly sapanisertib compared with fulvestrant alone.

The study will enroll approximately 153 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

• Fulvestrant 500 mg
• Fulvestrant 500 mg + Sapanisertib 4 mg
• Fulvestrant 500 mg + Sapanisertib 30 mg

All participants will receive either fulvestrant 500 mg intramuscularly (IM), fulvestrant 500 mg + sapanisertib 4 mg daily or fulvestrant 500 mg + sapanisertib 30 mg weekly.

This multicenter trial will be conducted Spain and the USA. Participants will make multiple visits to the clinic, and end of treatment (EOT) visit which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for progression free survival (PFS) and overall survival (OS).

• Study Type: Interventional
• Enrollment (Actual): 141
• Phase: Phase 2

Contacts and Locations

Study Locations

• Spain
  • A Coruna, Spain, 15006
    • Complejo Hospitalario Universitario A Coruña
  • A Coruna, Spain, 15009
    • Centro Oncologico de Galicia
  • Barcelona, Spain, 08035
    • Hospital Universitari Vall d'Hebron
  • Barcelona, Spain, 08036
    • Hospital Clinic I Provincial
  • Barcelona, Spain, 08041
    • Hospital de La Santa Creu i Sant Pau
  • Caceres, Spain, 10003
    • Hospital San Pedro De Alcantara
  • Lleida, Spain, 25198
    • Hospital Universitari Arnau de Vilanova de Lleida
  • Madrid, Spain, 28034
    • Hospital Universitario Ramon y Cajal
  • Madrid, Spain, 28040
    • Hospital Clinico San Carlos
  • Madrid, Spain, 28009
    • Hospital General Universitario Gregorio Marañón
  • Murcia, Spain, 30120
    • Hospital Clínico Universitario Virgen de la Arrixaca
  • Murcia, Spain, 30008
    • Hospital General Universitario Morales Messeguer
  • Sevilla, Spain, 41009
    • Hospital Universitario Virgen De La Macarena
  • Valencia, Spain, 46009
    • Fundación Instituto Valenciano de Oncología
  • Valencia, Spain, 46010
    • Hospital Clínico Universitario de Valencia
  • Zaragoza, Spain, 50009
    • Hospital Universitario Miguel Servet
  • Barcelona
    • Terrassa, Barcelona, Spain, 08827
      • Consorci Sanitari de Terrassa
  • Guipuzcoa
    • San Sebastian, Guipuzcoa, Spain, 20014
      • Onkologikoa
  • Islas Baleares
    • Palma de Mallorca, Islas Baleares, Spain, 07198
      • Hospital Son Llatzer
    • Palma de Mallorca, Islas Baleares, Spain, 07120
      • Hospital Universitari Son Espases
  • Madrid
    • Majadahonda, Madrid, Spain, 28220
      • Hospital Universitario Puerta del Hierro
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Clinica Universidad de Navarra
  • Tarragona
    • Reus, Tarragona, Spain, 43204
      • Hospital Universitario Sant Joan de Reus
• United States
  • Alabama
    • Mobile, Alabama, United States, 36608
      • Southern Cancer Center, PC
  • California
    • Bakersfield, California, United States, 93309
      • CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA
    • Fullerton, California, United States, 92835
      • St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare
    • La Jolla, California, United States, 92037
      • UCSD Moores Cancer Center
    • Los Angeles, California, United States, 90095-7077
      • UCLA Hematology/Oncology David Geffen School of Medicine
    • Oceanside, California, United States, 92056
      • North County Oncology
    • Redondo Beach, California, United States, 90277
      • Torrance Health Association
    • San Luis Obispo, California, United States, 93401
      • PHC-SLO Oncology and Hematology
    • Santa Barbara, California, United States, 93105
      • Cancer Center of Santa Barbara with Sansum Clinic
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP)
    • Grand Junction, Colorado, United States, 81501
      • St. Mary'S Hospital Regional Cancer Center
    • Lakewood, Colorado, United States, 80228
      • Rocky Mountain Cancer Centers LLP
  • Florida
    • Fort Lauderdale, Florida, United States, 33308
      • Holy Cross Hospital- Bienes Cancer Center
    • Hollywood, Florida, United States, 33021
      • Memorial Healthcare System
    • Orlando, Florida, United States, 33806
      • Orlando Health Inc.
  • Indiana
    • Fort Wayne, Indiana, United States, 46804
      • Ft. Wayne Medical Oncology and Hematology, Inc
  • Maine
    • Scarborough, Maine, United States, 04074
      • New England Cancer Specialists
  • Minnesota
    • Saint Louis Park, Minnesota, United States, 55426
      • Health Partners Institute Park Nicollet Frauenshuh Cancer Center
  • Nevada
    • Henderson, Nevada, United States, 89074
      • Comprehensive Cancer Centers of Nevada
  • New Jersey
    • Brick, New Jersey, United States, 8724
      • New Jersey Hematology & Oncology Associates
  • New York
    • Mount Kisco, New York, United States, 10549
      • Northern Westchester Hospital Cancer Treatment & Wellness Center
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health and Science University
  • Texas
    • Austin, Texas, United States, 78745
      • Texas Oncology, P.A.
    • Dallas, Texas, United States, 75246
      • Texas Oncology, P.A.
    • Dallas, Texas, United States, 75231
      • Texas Oncology - Presbyterian Hospital
    • McAllen, Texas, United States, 78503
      • Texas Oncology- South Second Street
    • San Antonio, Texas, United States, 78217
      • Cancer Care Centers of South Texas
    • Tyler, Texas, United States, 75702
      • Texas Oncology,PA. Tyler TX, 75702
  • Virginia
    • Leesburg, Virginia, United States, 20176
      • Virginia Cancer Specialist PC
  • West Virginia
    • Morgantown, West Virginia, United States, 26505
      • West Virginia University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Female participants aged 18 years or older who are postmenopausal.
2. Histologically proven diagnosis of breast cancer with evidence of metastatic disease or locoregional recurrence.
3. Histological confirmation and documentation of estrogen receptor (ER)-positive status (≥1% positive stained cells).
4. Histological or cytological confirmation and documentation of human epidermal growth factor receptor-2 (HER2)-negative status by local laboratory testing using criteria in the American Society of Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline update.

5. Measurable disease defined as either of the following:

   • At least 1 extra-osseous lesion that could be accurately measured in at least 1 dimension.
   • The lesion must have measured ≥20 mm with conventional imaging techniques or ≥10 mm with spiral CT or MRI. Lymph nodes must be ≥1.5 cm in the short axis to be considered measurable.
   • Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable disease as defined above. Note: Participants with sclerotic/osteoblastic bone lesions only, in the absence of measurable disease, were not eligible.
6. Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.

7. Have a history of brain metastasis provided that all of the following criteria are met:

   • Brain metastases have been treated.
   • No evidence of PD for ≥3 months before the first dose of study drug.
   • No hemorrhage after treatment.
   • Off dexamethasone treatment for ≥4 weeks before the first dose of study drug.
   • No ongoing requirement for dexamethasone or anti-epileptic drugs.
8. Eastern cooperative oncology group (ECOG) performance status of 0 or 1.

9. Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:

   • Bone marrow reserve consistent with absolute neutrophil count (ANC) ≥1.5*10^9/L; platelet count ≥100*10^9/L; hemoglobin (Hgb) ≥9 g/dL.
   • Total bilirubin ≤1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5*ULN (≤5*ULN if liver metastases are present).
   • Creatinine clearance ≥40 mL/min based on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.
   • Fasting serum glucose ≤130 mg/dL and fasting triglycerides ≤300 mg/dL.

Exclusion Criteria:

1. Prior therapy with mechanistic target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K), or dual PI3K-mTOR inhibitors, serine/threonine-specific protein kinase (AKT) inhibitors, or fulvestrant.
2. Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
3. Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
4. Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).
5. Poorly controlled diabetes mellitus defined as hemoglobin A1c (glycosylated hemoglobin; HbA1c) >7%; participants with a history of transient glucose intolerance due to corticosteroid administration may be eligible if all other inclusion/exclusion criteria are met.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Fulvestrant 500 mg; Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).	Drug: Fulvestrant; Fulvestrant IM injection.
EXPERIMENTAL: Fulvestrant 500 mg + Sapanisertib 4 mg; Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).	Drug: Fulvestrant; Fulvestrant IM injection.; Drug: Sapanisertib; Sapanisertib capsule.; Other Names: MLN0128
EXPERIMENTAL: Fulvestrant 500 mg + Sapanisertib 30 mg; Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).	Drug: Fulvestrant; Fulvestrant IM injection.; Drug: Sapanisertib; Sapanisertib capsule.; Other Names: MLN0128

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Up to 40 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	OS was defined as the time from the date of randomization to the date of death.	Up to 164 weeks
Time to Progression (TTP)	TTP was defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Up to 40 months
Objective Response Rate (ORR)	ORR was defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.	Up to 40 months
Clinical Benefit Rate (CBR)	CBR was defined as the percentage of participants who achieved a best response of CR, PR, or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.	Up to 40 months
Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.	Up to 164 weeks

Collaborators and Investigators

• Sponsor: Calithera Biosciences, Inc

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 28, 2016
• Primary Completion (ACTUAL): November 25, 2019
• Study Completion (ACTUAL): November 25, 2019

Study Registration Dates

• First Submitted: April 28, 2016
• First Submitted That Met QC Criteria: April 28, 2016
• First Posted (ESTIMATE): April 29, 2016

Study Record Updates

• Last Update Posted (ACTUAL): February 8, 2023
• Last Update Submitted That Met QC Criteria: February 6, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Drug Therapy
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Estrogen Antagonists; Estrogen Receptor Antagonists; Fulvestrant
• Other Study ID Numbers: C31006; 2015-003612-20 (EUDRACT_NUMBER); U1111-1174-2165 (REGISTRY: WHO)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
• IPD Sharing Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No